Literature DB >> 29190092

Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.

Tino Heimburg1, Fiona R Kolbinger2,3,4, Patrik Zeyen1, Ehab Ghazy1, Daniel Herp5, Karin Schmidtkunz5, Jelena Melesina1, Tajith Baba Shaik6, Frank Erdmann1, Matthias Schmidt1, Christophe Romier6, Dina Robaa1, Olaf Witt2,3,4,7, Ina Oehme2,3,4, Manfred Jung5, Wolfgang Sippl1.   

Abstract

Histone deacetylases (HDACs) are important modulators of epigenetic gene regulation and additionally control the activity of non-histone protein substrates. While for HDACs 1-3 and 6 many potent selective inhibitors have been obtained, for other subtypes much less is known on selective inhibitors and the consequences of their inhibition. The present report describes the development of substituted benzhydroxamic acids as potent and selective HDAC8 inhibitors. Docking studies using available crystal structures have been used for structure-based optimization of this series of compounds. Within this study, we have investigated the role of HDAC8 in the proliferation of cancer cells and optimized hits for potency and selectivity, both in vitro and in cell culture. The combination of structure-based design, synthesis, and in vitro screening to cellular testing resulted in potent and selective HDAC8 inhibitors that showed anti-neuroblastoma activity in cellular testing.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29190092     DOI: 10.1021/acs.jmedchem.7b01447

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity.

Authors:  Nina Reßing; Viktoria Marquardt; Christoph G W Gertzen; Andrea Schöler; Alexander Schramm; Thomas Kurz; Holger Gohlke; Achim Aigner; Marc Remke; Finn K Hansen
Journal:  Medchemcomm       Date:  2018-10-23       Impact factor: 3.597

2.  Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells.

Authors:  Patrik Zeyen; Yanira Zeyn; Daniel Herp; Fereshteh Mahmoudi; Talha Z Yesiloglu; Frank Erdmann; Matthias Schmidt; Dina Robaa; Christophe Romier; Johannes Ridinger; Corey J Herbst-Gervasoni; David W Christianson; Ina Oehme; Manfred Jung; Oliver H Krämer; Wolfgang Sippl
Journal:  Eur J Med Chem       Date:  2022-03-11       Impact factor: 6.514

3.  Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting Chimeras.

Authors:  Salma Darwish; Tino Heimburg; Johannes Ridinger; Daniel Herp; Matthias Schmidt; Christophe Romier; Manfred Jung; Ina Oehme; Wolfgang Sippl
Journal:  Methods Mol Biol       Date:  2023

4.  Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis.

Authors:  Mohammad-Nazir Menbari; Karim Rahimi; Abbas Ahmadi; Samira Mohammadi-Yegane; Anvar Elyasi; Nikoo Darvishi; Vahedeh Hosseini; Mohammad Abdi
Journal:  Iran Biomed J       Date:  2020-05-02

5.  The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.

Authors:  Fiona R Kolbinger; Emily Koeneke; Johannes Ridinger; Tino Heimburg; Michael Müller; Theresa Bayer; Wolfgang Sippl; Manfred Jung; Nikolas Gunkel; Aubry K Miller; Frank Westermann; Olaf Witt; Ina Oehme
Journal:  Arch Toxicol       Date:  2018-06-09       Impact factor: 5.153

6.  A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.

Authors:  Jing Shen; Sara Najafi; Sina Stäble; Johannes Fabian; Emily Koeneke; Fiona R Kolbinger; Jagoda K Wrobel; Benjamin Meder; Martin Distel; Tino Heimburg; Wolfgang Sippl; Manfred Jung; Heike Peterziel; Dominique Kranz; Michael Boutros; Frank Westermann; Olaf Witt; Ina Oehme
Journal:  Cell Death Differ       Date:  2018-03-07       Impact factor: 15.828

7.  The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs.

Authors:  Hugo Rolando Vaca; Ana María Celentano; María Agustina Toscanini; Tino Heimburg; Ehab Ghazy; Patrik Zeyen; Alexander-Thomas Hauser; Guilherme Oliveira; María Celina Elissondo; Manfred Jung; Wolfgang Sippl; Federico Camicia; Mara Cecilia Rosenzvit
Journal:  PLoS Negl Trop Dis       Date:  2021-03-03

8.  Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.

Authors:  Hany S Ibrahim; Mohamed Abdelsalam; Yanira Zeyn; Matthes Zessin; Al-Hassan M Mustafa; Marten A Fischer; Patrik Zeyen; Ping Sun; Emre F Bülbül; Anita Vecchio; Frank Erdmann; Matthias Schmidt; Dina Robaa; Cyril Barinka; Christophe Romier; Mike Schutkowski; Oliver H Krämer; Wolfgang Sippl
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

9.  First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement.

Authors:  Daniel Herp; Johannes Ridinger; Dina Robaa; Stephen A Shinsky; Karin Schmidtkunz; Talha Z Yesiloglu; Theresa Bayer; Raphael R Steimbach; Corey J Herbst-Gervasoni; Annika Merz; Christophe Romier; Peter Sehr; Nikolas Gunkel; Aubry K Miller; David W Christianson; Ina Oehme; Wolfgang Sippl; Manfred Jung
Journal:  Chembiochem       Date:  2022-06-10       Impact factor: 3.461

10.  Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity.

Authors:  Salma Darwish; Ehab Ghazy; Tino Heimburg; Daniel Herp; Patrik Zeyen; Rabia Salem-Altintas; Johannes Ridinger; Dina Robaa; Karin Schmidtkunz; Frank Erdmann; Matthias Schmidt; Christophe Romier; Manfred Jung; Ina Oehme; Wolfgang Sippl
Journal:  Int J Mol Sci       Date:  2022-07-07       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.